

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(Incorporated in the Cayman Islands as an exempted company with limited liability)*

**(Stock code: 1873)**

## **PROFIT WARNING**

This announcement is made by Viva Biotech Holdings (the “**Company**”, together with its subsidiaries, collectively referred to as the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company (the “**Director(s)**”) wishes to inform the shareholders of the Company (“**Shareholders**”) and potential investors that, based on the preliminary assessment of the latest unaudited management accounts of the Group and information currently available, for the six months ended June 30, 2022 (the “**Period**”), revenue of the Group is expected to increase by over 5% as compared with the corresponding period of last year, of which revenue from the CRO business is expected to increase by over 25%, and revenue from the CDMO business is expected to remain relatively stable; and the Group is expected to record a net loss of not more than RMB100 million for the Period as compared to the net profit of RMB95.8 million reported for the six months ended June 30, 2021. Based on the information currently available, the Board considers that the net loss is mainly attributable to (i) the resurgence of COVID-19 in mainland China limiting delivery of the Group’s products and services to customers during the Period; (ii) market fluctuation resulting in negative fair value changes in the Group’s equity interest in incubation portfolio companies; and (iii) fluctuation of foreign exchange rates during the Period resulting in foreign exchange losses for the Group.

In addition, it is expected that the adjusted net profit of the Group, being a non-International Financial Reporting Standards (“**IFRS**”) measure, for the six months ended June 30, 2022, will be approximately RMB80 million, representing a decrease from the adjusted net profit of the Group for the six months ended June 30, 2021.

The adjusted net profit of the Group is presented to supplement the Group’s consolidated financial statements which are presented in accordance with IFRS, and has adjusted the impact of (i) fair value (gain)/loss on embedded derivative instruments of convertible bonds issued by the Group; (ii) interest expenses of the debt components of convertible bonds issued by the Group; (iii) (gain)/loss on repurchase of convertible bonds issued by the Group; (iv) loss on disposal of non-recurring fixed assets; (v) amortization of acquired assets from acquisition and (vi) foreign exchange (gain)/loss.

The Company is in the process of preparing the unaudited condensed interim results for the Period. The information contained in this announcement is based on a preliminary assessment of the unaudited consolidated management accounts currently available to the Company, which is subject to finalization and other potential adjustments (if any) and has not been audited or reviewed by the Company's auditors or the audit committee of the Company. Details of the Group's performance will be disclosed in the interim results announcement of the Company for the Period, which is expected to be published by the end of August 2022.

**The Company believes that the adjusted non-IFRS financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Company's management and investors may benefit from referring to these adjusted financial measures in assessing the Group's financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that the Group does not consider indicative of the performance of the Group's business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the adjusted results on a stand-alone basis or as a substitute for results under the IFRS. Shareholders and potential investors are advised to exercise caution when dealing in shares of the Company.**

By order of the Board  
**Viva Biotech Holdings**  
**Mao Chen Cheney**  
*Chairman and Chief Executive Officer*

Hong Kong, August 12, 2022

*As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; a Non-executive Director, namely, Ms. Sun Yanyan; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.*